IL6 and metabolic dysfunction-associated steatotic liver disease: Similarly, IL-6 activates hepatic stellate cells, exacerbating liver damage.[46–50] The systemic inflammatory burden in RA fosters an environment conducive to NAFLD progression, suggesting that controlling inflammation may help mitigate liver-related complications in these patients.